Schiff Acted as Underwriters’ Counsel in GT Biopharma’s $23.7M Nasdaq Up-Listing Offering

News

Schiff Acted as Underwriters’ Counsel in GT Biopharma’s $23.7M Nasdaq Up-Listing Offering

News Release |

Schiff Hardin LLP advised Dawson James Securities, Inc. as underwriter in GT Biopharma, Inc.’s Nasdaq up-listing offering of 4.3 million units. Gross proceeds from the offering are approximately $23.7 million. GT Biopharma is a clinical stage biopharmaceutical company focused on the development and commercialization of immunology therapeutic products based on its proprietary trispecific killer engagers (TriKE™) target-directed natural killer cell engager platform. The offering closed on Feb. 17, 2021.